List of Excipients in Branded Drug OSELTAMIVIR

Generic Drugs Containing OSELTAMIVIR

Company	Ingredient	NDC	Excipient
Laurus Labs Limited	oseltamivir phosphate	42385-985	CROSCARMELLOSE SODIUM
Laurus Labs Limited	oseltamivir phosphate	42385-985	FD&C BLUE NO. 2 ALUMINUM LAKE
Laurus Labs Limited	oseltamivir phosphate	42385-985	FERRIC OXIDE YELLOW

What are the Most Frequently-Used Excipients in OSELTAMIVIR?

# Of NDCs	Excipient
3	CROSCARMELLOSE SODIUM
2	FD&C BLUE NO. 2
1	FD&C BLUE NO. 2 ALUMINUM LAKE

Last updated: August 4, 2026

Oseltamivir is a mature, genericized antiviral with limited active-ingredient exclusivity but meaningful excipient-driven commercial opportunities. The strongest opportunities are pediatric oral suspension, palatability, low-water-activity dry formulations, emergency stockpile stability, dose flexibility, and supply-chain resilience. The principal commercial constraint is price competition from generic capsules and the availability of pharmacy-compounded suspension from capsules or powder.

Oseltamivir Excipient Strategy and Commercial Opportunities

Oseltamivir phosphate is the prodrug of oseltamivir carboxylate, an influenza A and B neuraminidase inhibitor. Roche commercialized it as Tamiflu under a license from Gilead Sciences. The drug is approved in the United States for treatment and prophylaxis of influenza in patients ranging from infants to adults, subject to age and dosing requirements.[1]

Oseltamivir is now a mature small-molecule product. The commercial opportunity has shifted from molecule exclusivity to formulation execution, pediatric usability, emergency preparedness, manufacturing economics, and differentiated distribution.

What excipients are used in oseltamivir products?

Commercial oseltamivir products use relatively conventional excipient systems. The exact composition varies by manufacturer, dosage form, market, and product strength.

Oseltamivir capsules

Tamiflu capsules contain oseltamivir phosphate equivalent to 30 mg, 45 mg, or 75 mg of oseltamivir, depending on strength. The capsule-fill formulation includes excipients such as:

• Croscarmellose sodium
• Povidone
• Sodium stearyl fumarate
• Talc
• Pregelatinized starch or related diluent systems, depending on product
• Gelatin capsule shells
• Titanium dioxide
• Colorants, including iron oxides or FD&C dyes in some strengths

Generic products may use different fillers, disintegrants, lubricants, capsule-shell materials, and colorants while maintaining pharmaceutical equivalence and dissolution performance.[2]

Capsules are operationally attractive because they have high manufacturing throughput, low packaging complexity, good dose uniformity, and comparatively long shelf life. Their weakness is administration in infants, young children, and patients who cannot swallow solid dosage forms.

Oseltamivir oral suspension

The branded Tamiflu oral suspension is supplied as a powder for constitution. The powder typically contains:

• Sorbitol
• Sodium citrate
• Xanthan gum
• Sodium benzoate
• Saccharin sodium
• Titanium dioxide
• Flavoring agents
• Pharmaceutical-grade excipients that support suspension uniformity and palatability

The constituted suspension has a limited in-use period and requires controlled storage. The label permits pharmacists to compound a suspension from capsules when the commercial suspension is unavailable, using a vehicle such as Ora-Sweet SF or an equivalent sugar-free vehicle under specified procedures.[1]

The suspension creates more formulation value than the capsule because the product must solve several technical problems at once: dose accuracy, sedimentation control, taste masking, microbial preservation, chemical stability, and administration through oral syringes.

What formulation challenges affect oseltamivir excipient selection?

Oseltamivir formulation development is driven by the phosphate salt, the prodrug’s aqueous behavior, pediatric taste, and the need for reliable dosing during influenza outbreaks.

Palatability

Taste is a primary barrier in pediatric antiviral adherence. Oseltamivir suspension has a bitter or medicinal taste profile that requires sweeteners and flavors. Sorbitol, saccharin sodium, and flavor systems can improve acceptability, but they also create formulation tradeoffs:

• Sorbitol can cause gastrointestinal discomfort at higher exposure.
• High sweetener loads can affect viscosity and osmolarity.
• Flavor systems can interact with preservatives or packaging materials.
• Pediatric populations may require age-specific taste profiles.
• Sugar-free formulations are preferable for some patients but may have higher excipient complexity.

A differentiated product could target better taste masking with ion-exchange resins, lipid-based taste-masking systems, cyclodextrins, polymer coatings, or multiparticulate dosage forms. Any such approach would need to preserve rapid release and avoid reducing systemic exposure.

Suspension uniformity

A pediatric suspension must redisperse quickly after standing and provide consistent dosing throughout the bottle. Xanthan gum and related suspending agents help control sedimentation, but excessive viscosity can make oral-syringe withdrawal difficult.

The target formulation should balance:

1. Low sedimentation rate.
2. Rapid redispersion with modest shaking.
3. Accurate withdrawal through a dosing syringe.
4. Acceptable mouthfeel.
5. Stable viscosity over the labeled shelf life.

Suspension rheology is commercially relevant because a product with poor redispersion can create underdosing or overdosing even when the active ingredient and nominal concentration are correct.

Chemical and microbiological stability

Oseltamivir suspension requires protection against microbial growth after constitution. Sodium benzoate and low-pH buffering may support preservation, while packaging and water quality affect the final product.

A formulation intended for emergency stockpiles should minimize post-constitution complexity. Dry powder products have advantages because they reduce the amount of water present during storage and can improve microbial stability before dispensing. The commercial product still must demonstrate stability after reconstitution under the labeled storage conditions.[1]

Pediatric dose flexibility

Treatment and prophylaxis doses vary by age and weight. A suspension concentration that is too high may increase dosing errors in small children. A concentration that is too low increases bottle volume, shipping weight, and administration burden.

The 6 mg/mL concentration used for Tamiflu suspension provides a practical basis for pediatric dosing, but alternative concentrations could support:

• Neonatal and infant dosing
• Weight-band dosing
• Lower administration volumes
• Hospital protocols
• Emergency compounding
• Use through enteral feeding tubes

A higher concentration may be commercially attractive for older children and adults who cannot swallow capsules. A lower concentration may be more appropriate where small-volume measurement is not the primary concern.

What commercial oseltamivir dosage forms have the strongest opportunity?

The commercial opportunity is concentrated in dosage forms that improve access or reduce operational friction.

Dosage form	Primary benefit	Main excipient opportunity	Commercial outlook
30 mg, 45 mg, 75 mg capsules	Low-cost, scalable dosing	Improved disintegration, allergen-free capsule shells, colorant-free shells	Highly competitive
Powder for oral suspension	Pediatric and dysphagia use	Taste masking, preservation, rheology, stability	Stronger differentiation
Ready-to-use suspension	No pharmacy constitution	Preservative and packaging optimization	Convenience premium, higher logistics cost
Orodispersible tablet	No water required	Superdisintegrants, taste masking, mannitol-based matrices	Potential niche opportunity
Oral granules or sachets	Flexible administration and shipping	Granule coating, moisture protection, flavoring	Useful for pediatric and institutional markets
Feeding-tube formulation	Hospital and long-term-care use	Low-viscosity vehicle, tube compatibility	Specialized opportunity
Extemporaneous compounding kit	Supply continuity	Vehicle, measuring device, instructions	Stockpile and shortage-response opportunity

Capsules are difficult to differentiate through excipients alone because generic manufacturers can change many inactive ingredients while preserving bioequivalence. Suspension and alternative oral formats offer more defensible product value.

How can excipient suppliers create value in oseltamivir?

Excipient suppliers can participate through platform technologies rather than commodity supply alone.

Taste-masking systems

A ready-to-use taste-masking system could combine a hydrophobic coating with rapid release in the gastrointestinal tract. The most relevant technologies include:

• Polymer-coated drug particles
• Lipid-based microparticles
• Ion-exchange complexes
• Cyclodextrin inclusion systems
• Functional excipient blends
• Flavor and sweetener systems optimized for bitterness suppression

The technical target is rapid release after swallowing without a meaningful increase in dose volume or sedimentation.

Low-viscosity suspension systems

A supplier could offer a prequalified suspension base with:

• Controlled yield stress
• Rapid redispersion
• Low syringe withdrawal force
• Compatible preservative performance
• Stable pH
• Reduced foaming during shaking

Such a platform could be licensed to generic manufacturers or used in hospital-compounding products.

Pediatric-friendly preservative systems

Preservative selection is constrained by age, exposure, regulatory status, and compatibility with the active ingredient. Sodium benzoate is established in oseltamivir suspension, but alternative systems could support products with improved taste, reduced preservative burden, or better multidose stability.

The regulatory value would depend on whether the alternative excipient is already accepted in oral pediatric products and whether the finished formulation avoids new safety questions.

Packaging-linked excipient solutions

Moisture-barrier bottles, induction seals, desiccants, child-resistant closures, and oral syringes are part of the formulation commercialization strategy. A dry powder product with a high-barrier package may have better stockpile performance than a liquid product but still requires reliable reconstitution at the point of use.

What FDA regulatory status does oseltamivir have?

The FDA approved Tamiflu in 1999 for treatment of influenza in adults.[3] The agency later expanded the product for prophylaxis and younger pediatric populations. Current labeling includes treatment and prophylaxis indications for influenza A and B, with dosing determined by age, weight, renal function, and treatment or prevention status.[1]

Oseltamivir phosphate is an approved small-molecule drug. It is regulated through the abbreviated new drug application pathway for generic products, not the biosimilar pathway.

Is oseltamivir a biologic or biosimilar product?

No. Oseltamivir is a chemically synthesized small molecule. Biosimilar risk is therefore not relevant. Competitive risk comes from conventional generic versions, authorized products, compounded suspension, and alternative influenza antivirals such as baloxavir marboxil and zanamivir.

What is the Orange Book status of oseltamivir?

The original Tamiflu patents and regulatory exclusivities have expired. FDA-listed generic products compete primarily through abbreviated new drug applications. The Orange Book remains relevant for identifying listed reference products, therapeutic equivalence ratings, and any patent or exclusivity information associated with specific products.[4]

The practical implication is that a new oseltamivir formulation generally cannot rely on composition-of-matter exclusivity. Its regulatory strategy must be based on one or more of the following:

• A 505(b)(2) application for a differentiated dosage form
• An abbreviated new drug application for a conventional generic
• A new formulation with clinical or usability advantages
• Device or packaging differentiation
• Contracting and supply reliability

When did oseltamivir lose core patent exclusivity?

Gilead’s oseltamivir patent estate was licensed to Roche for Tamiflu commercialization. The principal U.S. compound patent, U.S. Patent No. 5,952,375, was issued in 1999 and had an expiration date in 2016, subject to any applicable patent-term adjustment or extension. FDA pediatric exclusivity and related regulatory protections extended commercial protection beyond the basic patent period in some markets.[5]

The core compound estate is no longer a meaningful barrier to generic entry. Any current patent risk would more likely involve a specific formulation, manufacturing process, salt, dosing method, or device rather than oseltamivir itself.

What patents could protect a new oseltamivir excipient formulation?

A new product would need claims directed to a genuine technical distinction. Potential claim categories include:

Formulation patents

Potentially protectable subject matter includes:

• A defined oseltamivir concentration range
• A specific sweetener and flavor combination
• A rheology profile
• A preservative system
• A particle-size distribution
• A taste-masked microparticle
• A moisture-controlled powder
• A ready-to-use suspension with extended stability
• A composition compatible with feeding tubes

Broad claims covering oseltamivir plus ordinary excipients would face validity and obviousness risk. Narrow claims tied to measurable performance attributes have a stronger chance of surviving examination and later litigation.

Method-of-use patents

Method claims could focus on:

• Administration to specified pediatric age groups
• Use through enteral feeding tubes
• Reduced-volume dosing
• Improved adherence through taste masking
• Emergency reconstitution procedures
• Use in patients with swallowing impairment

Method-of-use protection may be commercially useful but is difficult to enforce against ordinary generic sales when the same product has approved treatment and prophylaxis uses.

Manufacturing patents

Manufacturing claims may cover:

• Low-water-activity granulation
• Continuous production of suspension powder
• Controlled particle coating
• Improved yield or impurity control
• Stable phosphate-salt processing
• Aseptic or low-bioburden packaging operations

Manufacturing patents can create barriers where the process materially reduces cost or improves stockpile stability. Their value depends on whether an alternative process is commercially practical.

Are there Paragraph IV challenges to oseltamivir?

Paragraph IV litigation was most relevant during the initial generic-entry period after core Tamiflu exclusivity ended. Generic manufacturers could challenge listed patents by certifying that patents were invalid, unenforceable, or not infringed under the Hatch-Waxman framework.

Oseltamivir is now a mature generic market. The principal competitive question is not whether a new applicant can enter after a Paragraph IV challenge, but whether a differentiated formulation can obtain meaningful market share without provoking litigation over residual formulation or method patents.

A new excipient product relying on a 505(b)(2) pathway could face patent certifications if the reference product or related products have relevant listed patents. A conventional generic capsule usually faces a lower formulation-IP burden, but it also has less differentiation.

What litigation and settlement issues affect oseltamivir?

The major historical dispute involved Roche’s Tamiflu commercialization rights and licensing relationship with Gilead, rather than a current formulation patent conflict. Roche and Gilead entered into an agreement under which Roche commercialized oseltamivir, with later disputes concerning royalty calculations and contractual rights.[6]

For a new oseltamivir formulation, the material legal risks would be:

• Orange Book-listed patents for the reference product
• Patent claims covering a specific suspension or delivery format
• Trade dress and packaging claims
• Contract restrictions in government procurement
• Manufacturing know-how held by incumbent suppliers
• Antitrust or supply-allocation issues in stockpile contracting

No broad active composition-of-matter patent should be assumed to block entry. The relevant freedom-to-operate analysis must focus on the exact formulation, process, package, and labeled use.

How does oseltamivir compare with competing influenza antivirals?

Product	Active ingredient	Dosage forms	Key commercial differentiator	Excipient opportunity
Tamiflu and generics	Oseltamivir phosphate	Capsules, oral suspension	Broad age use and oral administration	Pediatric taste, suspension stability
Xofluza	Baloxavir marboxil	Tablet, oral granules in some markets	Single-dose treatment	Pediatric granules and dosing convenience
Relenza	Zanamivir	Inhaled powder	Local respiratory delivery	Device and powder-flow performance
Rapivab	Peramivir	Intravenous infusion	Hospital administration	Infusion compatibility and stability

Oseltamivir retains a broad use case because it is orally administered, available in multiple capsule strengths, and used for both treatment and prophylaxis. Baloxavir’s single-dose regimen creates adherence pressure, while oseltamivir’s established pediatric and public-health role supports continued institutional demand.[1,7]

What generic entry risks exist for an oseltamivir formulation?

The principal risks are commercial rather than molecule-patent related.

Price erosion

Generic capsules can rapidly reduce average selling prices. A new capsule product with conventional excipients is unlikely to sustain a substantial premium unless it has procurement, supply, or quality advantages.

Pharmacy compounding

When commercial suspension is unavailable, pharmacies can compound oseltamivir suspension from capsules under FDA-recognized procedures. This creates a substitute for a dedicated pediatric suspension, particularly during seasonal shortages.[1]

Seasonal demand volatility

Influenza demand is highly seasonal and can change sharply during outbreaks. Manufacturers must manage:

• Active pharmaceutical ingredient inventory
• Excipient and packaging capacity
• Long lead times for government tenders
• Expiry and stock rotation
• Regional demand differences
• Emergency release requirements

Supply-chain concentration

A suspension product can have more supply dependencies than capsules because it requires specialized flavors, suspending agents, preservatives, bottles, adapters, and oral syringes. A manufacturer with dual-source excipients and packaging can create value even without patent differentiation.

What licensing deals could support an oseltamivir excipient product?

Licensing opportunities exist at several levels:

1. An excipient supplier could license a taste-masking or suspension platform to a generic manufacturer.
2. A generic manufacturer could partner with a pediatric pharmaceutical company for a 505(b)(2) product.
3. A packaging company could provide a complete dry-powder, reconstitution, and dosing system.
4. A government supplier could obtain rights to a stable stockpile formulation.
5. A hospital-compounding company could commercialize a standardized kit using a validated vehicle and dosing device.

The strongest deal structure would align formulation IP with manufacturing capacity and procurement access. A standalone excipient patent without finished-product manufacturing or distribution rights is less likely to capture substantial value in a low-price generic market.

What is the revenue exposure to oseltamivir formulation innovation?

Revenue exposure is concentrated in influenza treatment and prevention volumes, government stockpiles, hospitals, retail pharmacies, and pediatric prescribing. The original Tamiflu franchise generated substantial global sales during pandemic and severe seasonal influenza periods, but current revenue is distributed across Roche, generic manufacturers, wholesalers, and public-sector buyers.[8]

A differentiated excipient product would most likely monetize through:

• A modest premium over generic capsules
• Higher margins on pediatric suspension
• Government and institutional contracts
• Emergency stockpile procurement
• Licensing royalties
• Contract manufacturing
• Supply agreements with pharmacy chains

The largest volume opportunity is conventional capsules. The largest margin opportunity is likely a reliable, palatable, pediatric-ready suspension or alternative oral format.

How strong is the patent estate for a new oseltamivir formulation?

The core oseltamivir patent estate is weak as a barrier to entry because the compound has long been genericized. A new formulation estate can be moderately strong only when it includes:

• Narrow but technically meaningful composition claims
• Demonstrated taste or stability benefits
• Distinctive particle or coating architecture
• Process claims that are difficult to design around
• Device and package integration
• Clinical or human-factor data supporting the product advantage

A formulation estate based only on routine excipient substitution is vulnerable to obviousness challenges and generic design-around strategies. Commercial defensibility should therefore combine patents with regulatory differentiation, supply reliability, procurement contracts, and manufacturing know-how.

Key Takeaways

• Oseltamivir is a mature generic antiviral with no meaningful current compound exclusivity barrier.
• Capsules are efficient but highly exposed to price competition.
• Pediatric suspension is the clearest excipient-led opportunity.
• Taste masking, suspension rheology, preservative selection, and post-constitution stability are the central formulation issues.
• Ready-to-use liquids, dry powder sachets, orodispersible tablets, and feeding-tube products can create differentiated niches.
• Pharmacy compounding limits the premium available for commercial suspension.
• A new product would likely require an ANDA, 505(b)(2) strategy, or a combination of formulation, device, and manufacturing differentiation.
• Patent value will depend on specific measurable formulation or process features, not broad claims to oseltamivir plus ordinary excipients.
• Government stockpiles and seasonal supply reliability can be as important as patent protection.
• The strongest commercial model combines pediatric usability, robust stability, dual-source excipients, and institutional procurement access.

FAQs

What is the best excipient for oseltamivir suspension?

Xanthan gum is a commonly used suspending agent, while sorbitol, saccharin sodium, flavoring, buffering agents, and sodium benzoate support palatability, pH control, preservation, and physical stability. The optimal system depends on target concentration, storage conditions, age group, and dosing device.[1]

Can oseltamivir capsules be used to make an oral suspension?

Yes. FDA-recognized compounding procedures permit pharmacies to prepare an oseltamivir suspension from capsules when commercial suspension is unavailable, subject to the applicable formulation and storage instructions.[1]

Is oseltamivir suspension more commercially defensible than capsules?

Usually. Suspension products require taste, rheology, preservation, packaging, and dosing performance that are harder to replicate than a conventional capsule-fill formulation. The market is still constrained by pharmacy compounding and generic price pressure.

Can an oseltamivir formulation receive new patent protection?

Yes, but protection would need to focus on a novel formulation, particle architecture, manufacturing process, dosing system, or specific method of use. Routine substitutions of common excipients would face substantial patentability risk.

Does oseltamivir compete with biosimilars?

No. Oseltamivir is a synthetic small molecule, so its competitive market consists of generics and other influenza antivirals rather than biosimilars.

References

1. U.S. Food and Drug Administration. (2024). Tamiflu (oseltamivir phosphate) prescribing information.
2. DailyMed. (2024). Oseltamivir phosphate capsule and oral suspension labeling. National Library of Medicine.
3. U.S. Food and Drug Administration. (1999). FDA approves Tamiflu for treatment of influenza.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
5. U.S. Patent No. 5,952,375. (1999). Cyclopentane derivatives. U.S. Patent and Trademark Office.
6. Gilead Sciences, Inc. (2005). Annual report and disclosures concerning oseltamivir licensing arrangements.
7. U.S. Food and Drug Administration. (2024). Influenza antiviral medications: Summary for clinicians.
8. Roche Holding AG. (2024). Annual report and pharmaceutical product disclosures.